Publication
Article
Pharmacy Times
Read about the new generic products featured in May.
FLUDARABINE PHOSPHATE
MARKETED BY: Teva Pharmaceutical Industries Ltd
COMPARE TO: Fludara
INDICATION: Teva announced the availability of Fludarabine Phosphate generic for injection, which is indicated for treating adults with B-cell chronic lymphocytic leukemia who have not responded to, or whose disease has progressed during treatment with, at least 1 standard alkylating agent—containing regimen.
DOSAGE FORM: Injection: 50 mg/2 mL
FOR MORE INFORMATION: Tevagenerics.com
DESVENLAFAXINE
MARKETED BY: Teva Pharmaceutical Industries Ltd
COMPARE TO: Pristiq
INDICATION: Teva announced the launch of generic Pristiq (desvenlafaxine) extended-release tablets of 25, 50, and 100 mg in the United States. Desvenlafaxine extended-release tablets are a serotonin and norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder.
DOSAGE FORM: Tablets: 25, 50, and 100 mg
FOR MORE INFORMATION: Tevapharm.com
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL TABLETS AND FERROUS FUMARATE TABLETS
MARKETED BY: Teva
COMPARE TO: Minastrin 24 Fe
INDICATION: Teva has announced the launch of an authorized generic of Minastrin 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) 1 mg/20 mcg in the United States. Minastrin 24 Fe is an estrogen/progestin combined oral contraceptive indicated for use by women to prevent pregnancy.
DOSAGE FORM: Tablets: 1 mg/20 mcg
FOR MORE INFORMATION: tevapharm.com
EXEMESTANE TABLETS, 25 MG
MARKETED BY: Mylan
COMPARE TO: Aromasin
INDICATION: Mylan has announced the US launch of its generic version of Pfizer’s Aromasin Tablets. Exemestane Tablets, 25 mg, is indicated for the treatment of certain types of breast cancer in women after menopause.
DOSAGE FORM: Tablets: 25 mg
FOR MORE INFORMATION: mylan.com